Compugen Ltd. (CGEN) receives analyst rating upgrade to Buy. Buy rating upgrade may lift near-term investor sentiment and trading activity for CGEN.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | 1 | 8 | — | — | 1 | — | — |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 51.05 | 103.26 | 145.64 | 125.30 |
| Receivables | 63.53 | 2.74 | 2.38 | 4.11 |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 114.58 | 106.00 | 148.02 | 129.41 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 3.50 | 1.84 | 2.35 | 2.16 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 26.27 | 20.16 | 22.57 | 22.63 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 2.18 | 2.60 | — | — |
—
|
| ’25 | 2.28 | 1.26 | 1.89 | 67.33 |
72.76
|
| ’24 | 2.56 | 6.70 | 17.13 | 1.47 |
27.86
|
| ’23 | — | — | — | — |
33.46
|
| ’22 | — | — | — | 7.50 |
7.50
|
| ’21 | — | — | 6.00 | — |
6.00
|
| ’20 | — | — | — | 2.00 |
2.00
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | (21.95) | — | — |
—
|
| ’25 | — | (18.56) | — | 31.63 |
31.63
|
| ’24 | — | 39.70 | — | 49.60 |
49.60
|
| ’23 | — | (18.57) | — | (35.89) |
(35.89)
|
| ’22 | — | (20.68) | — | (34.11) |
(34.11)
|
| ’21 | — | (13.63) | — | (22.75) |
(22.75)
|
| ’20 | — | (11.57) | — | (28.32) |
(28.32)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | (21.98) | — | — |
—
|
| ’25 | — | (18.79) | — | 31.33 |
31.33
|
| ’24 | — | 39.67 | — | 49.49 |
49.49
|
| ’23 | — | (18.64) | — | (36.06) |
(36.06)
|
| ’22 | — | (20.94) | — | (34.59) |
(34.59)
|
| ’21 | — | (13.85) | — | (23.04) |
(23.04)
|
| ’20 | — | (11.67) | — | (28.44) |
(28.44)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.08) | (0.07) | — | — |
—
|
| ’25 | (0.08) | (0.08) | (0.07) | 0.60 |
0.38
|
| ’24 | (0.08) | (0.02) | 0.01 | (0.07) |
(0.16)
|
| ’23 | (0.11) | (0.11) | (0.11) | 0.11 |
(0.21)
|
| ’22 | (0.11) | (0.11) | (0.14) | (0.04) |
(0.39)
|
| ’21 | (0.12) | (0.11) | (0.07) | (0.10) |
(0.41)
|
| ’20 | (0.10) | (0.08) | (0.09) | (0.10) |
(0.37)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 0.51 | 0.53 | 1.35 | 1.13 | — | — | — |
Low Price
|
| ‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 4.64 | 2.46 | 3.03 | 2.66 | — | — | — |
High Price
|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 69 | 68 | 74 | 75 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.11 | 0.49 | 0.38 | 0.97 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | — | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 7.50 | 33.46 | 27.86 | 72.76 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 87.00% | 94.01% | 71.54% | 87.29% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (33.64) | (9.78) | (9.71) | 35.40 | ‡‡‡‡‡ | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (448.48%) | (29.24%) | (34.84%) | 48.65% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (33.69) | (18.75) | (14.23) | 35.34 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.48 | 0.20 | (1.09) | (0.01) | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.09 | 0.38 | 0.31 | 0.78 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.39) | (0.21) | (0.16) | 0.38 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.39) | (0.41) | 0.55 | 0.34 | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.01) | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.40) | (0.41) | 0.55 | 0.34 | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.90 | 0.75 | 0.61 | 1.10 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 86.56 | 87.63 | 89.53 | 93.43 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| ‡‡‡ | — | ‡‡‡ | — | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 4.14 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| ‡‡‡‡‡ | — | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.96 | 11.31 | 4.92 | 1.96 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| ‡‡‡‡‡ | — | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.79 | 2.67 | 2.49 | 1.39 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| ‡‡‡‡‡ | — | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.31) | 8.10 | 1.26 | (0.02) | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| ‡‡‡‡‡ | — | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.22 | (1.14) | 1.02 | (0.01) | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (34.11) | (35.89) | 49.60 | 31.63 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.47) | (0.17) | (0.12) | (0.30) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (34.59) | (36.06) | 49.49 | 31.33 | ‡‡‡‡‡ | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 74.21 | 88.31 | 85.84 | 125.45 | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.93 | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (81.78) | (51.05) | (103.25) | (145.64) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 77.68 | 65.56 | 54.91 | 102.73 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (29.77%) | (17.40%) | (12.04%) | 26.03% | ‡‡‡‡‡ | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | (55.97%) | 0.00% | 0.00% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (36.55%) | (26.19%) | (23.63%) | 44.84% | ‡‡‡‡‡ | — | — |
ROE
|
Compugen Ltd. (CGEN), an Israel-based computational biology pioneer in cancer immunotherapy targets, navigates a treacherous landscape of Middle East geopolitical tensions and a biotech funding drought from prolonged high interest rates. Despite revenue volatility—peaking at $33.5 million in 2023 before a 17% drop to $27.9 million in 2024—the company achieved a remarkable turnaround with $49.5 million in positive free cash flow last year, fueled by milestone payments from partners like Bristol Myers Squibb and Gilead. This lean operation, with high revenue per employee and stable headcount, underscores improving efficiency amid narrowing losses, from -$33.7 million net income in 2022 to -$14.2 million in 2024.
CGEN’s balance sheet stands as a rare fortress in biotech’s winter, boasting $103.3 million in net cash—enough for over three years of opex—and negligible debt, shielding it from sector-wide dilution pressures. Valuation metrics scream undervaluation, with EV/Sales at a compressed 1.3x and positive EV/FCF at 1.0x, trading at a steep discount to peers and analyst targets implying 140-690% upside on pipeline catalysts like COM701 data.
Yet risks loom large: cyclical revenues forecast to trough in 2026, persistent losses, binary clinical trial outcomes, and Israel’s ongoing conflicts adding volatility. For risk-averse investors, CGEN’s cash hoard offers downside protection in a thawing biotech environment, but steady performers demand caution before chasing this high-reward turnaround.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.